NEW META-ANALYSIS CONFIRMS LDL-LOWERING REDUCES RISK

.....but a portion of the internet is still always quick to make the same tired old arguments that actually don't rebut the findings as well as they think they do. Here are the details....

A new meta-analysis just published in JACC (Journal of the American College of Cardiology) has provided the most comprehensive evidence to date on LDL-cholesterol lowering in primary prevention populations.

Key Findings:

-Analyzed 13 major cardiovascular outcome trials (CVOTs)

-Focused on people WITHOUT pre-existing heart disease (primary prevention)

-Found that each 1.0 mmol/L (39 mg/dL) reduction in LDL-C was associated with a 30% reduction in major cardiovascular events (relative risk 0.70, 95% CI 0.67-0.74)

-The benefit was consistent across all trials, regardless of baseline LDL levels

-Average absolute LDL reduction achieved: 1.0 mmol/L (39 mg/dL)

This represents data from hundreds of thousands of participants followed for years, showing clear, consistent, and clinically meaningful benefits.

(Study DOI: 10.1016/j.jacl.2026.02.006)

ADDRESSING THE CLASSIC "STATIN DENIER" ARGUMENTS:

Let's systematically address the common objections you'll see in comments sections across the internet and see how they hold up to scrutiny....

Claim #1: "What about absolute risk reduction? Relative risk is misleading!"

This is perhaps the most common deflection tactic. So yes, let's talk about absolute risk reduction (ARR).

The commenter here states "No primary prevention RCT has shown more than 1-3% ARR mortality."

First, to be clear, relative Risk Reduction (RRR) tells you the percentage decrease in risk compared to the control group, while Absolute Risk Reduction (ARR) tells you the actual percentage point difference in event rates between the two groups.

Second, this claim cherry-picks mortality alone while ignoring the composite endpoint of cardiovascular events (heart attacks, strokes, revascularizations) that cause enormous suffering, disability, and cost. I don't know about you, but I'm not only wanting prevent death from cardiovascular disease, I'd like to prevent heart attacks, strokes, vascular dementia, peripheral artery disease, declining kidney function, sexual dysfunction, and more as well.

Third, a 1-3% ARR in mortality is actually VERY SUBSTANTIAL anyways (when you understand the math):

-If baseline 10-year risk of dying for someone is 10%, and then you reduce that by 30% (the RRR), you get a 3% ARR

-That means treating 33 people without known cardiovascular disease with statins prevents 1 death over 10 years.

-Number Needed to Treat (NNT) of 33 is considered excellent for a preventive intervention

-For comparison, aspirin in secondary prevention has an NNT around 50-100

Fourth, importantly, ARR depends entirely on baseline risk. So in higher-risk primary prevention populations (family history, diabetes, chronic kidney disease, high coronary calcium scores), the ARR becomes much larger because the baseline risk is higher, while the RRR remains constant at ~30%.

The mathematics: ARR = RRR × Baseline Risk

So yes, in a truly low-risk 40-year-old with perfect health markers, the ARR might be small because their baseline risk is tiny. But in a 65-year-old with diabetes, hypertension, and LDL of 160 mg/dL, the same 30% RRR translates to a much larger ARR.

Claim #2: "The benefits are just a few extra days/weeks of life. Not impressive."

The Reality: This is a gross mischaracterization of the data around this topic.

First, the benefits shown in these trials include:

-Prevention of non-fatal heart attacks (which often lead to heart failure, reduced quality of life, and ongoing medical costs)

-Prevention of strokes (which cause disability, cognitive decline, and loss of independence)

-Prevention of coronary revascularization procedures (stents, bypasses)

-Mortality reduction

Saying this equates to "a few extra days of life" completely ignores:

-The quality of those years lived without a heart attack or stroke

-The prevention of disability and suffering

-The economic impact of avoiding cardiovascular events

-The benefit to families and caregivers

Second, the "few extra days" claim is actually mathematically dishonest anyway, because it averages the benefit across entire populations including very low-risk individuals who were never going to have an event. For your high-risk patients with FH, significant coronary calcium, or multiple risk factors, the benefit translates to years of quality life, not days.

Claim #3: Not a claim but a common misconception- People arguing against papers like these also ignore the fact that many trials continue monitoring things beyond the duration of the main trial and find the benefits continue, and typically amplify over time

-WOSCOPS extended follow-up: Benefits persisted and even amplified over 20 years

-JUPITER extended follow-up: Continued separation of event curves beyond the trial period

-CTT Collaboration meta-analyses: Consistent benefit across all follow-up durations

Ignoring effects of combination therapy that further lower LDL:

IMPROVE-IT: Adding ezetimibe to statin showed additional benefit proportional to additional LDL lowering

FOURIER and ODYSSEY: PCSK9 inhibitors added to statins showed additional cardiovascular benefit

The pattern is CRYSTAL CLEAR:

More LDL lowering = More benefit, regardless of how you achieve it (diet, statins, ezetimibe, PCSK9 inhibitors, bempedoic acid).

Claim #4: "Statins have terrible side effects that outweigh the benefits"

The Reality: This claim has been thoroughly debunked by N-of-1 trials and systematic reviews.

Key evidence:

-Muscle symptoms in randomized trials: ~1-5% in statin group vs ~1-3% in placebo group

-In blinded crossover (n-of-1) trials, when patients who "couldn't tolerate statins" were given statin vs placebo in random order without knowing which was which, 90% had the same symptoms on placebo as they did taking the statin

-This strongly suggests a nocebo effect (negative expectation causing symptoms) may be contributing in a significant number of reported statin side effects.

Serious side effects are rare:

-Rhabdomyolysis: ~1 in 10,000 patient-years

-New-onset diabetes: There can be legitimate increased risk, but the studies on this show cardiovascular benefit still far outweighs any blood sugar raising effect. In other words, despite blood sugar going up in some people, risk of cardiovascular disease events and deaths still goes down.

-Liver enzyme elevation: Usually transient and clinically insignificant

Also, these side effect risks are DOSE DEPENDENT- so the lower the dose the less potential risk there, but benefits can still be substantial even at low doses, especially if ezetimibe is added to further lower LDL, while keeping statin doses lower.

Claim #5: "This is all pharmaceutical industry propaganda"

While we should always scrutinize industry involvement, this conspiracy theory doesn't hold up.

Consider:

-Generic statins cost pennies per pill, so there's no massive profit motive anymore

-The trials in this meta-analysis include investigator-initiated studies, not just industry-sponsored trials

-The benefits have been replicated in trials of non-statin LDL-lowering drugs (ezetimibe, PCSK9 inhibitors, bempedoic acid) and LDL lowering diets. What matters is how low the LDL goes, not how it gets there.

-The mechanism is biologically plausible and supported by decades of atherosclerosis research

-Mendelian randomization studies (genetic studies free from confounding variables) show the same relationship: lifelong lower LDL = lower cardiovascular risk

If this were truly a grand conspiracy at play here, it would require:

-Falsifying data across hundreds of independent research groups

-Coordinating false results across different countries, institutions, and regulatory bodies

-Fooling cardiologists worldwide in their own practices, using their own eyeballs, who see the clinical benefits daily

-Somehow fudging data to make non-statin LDL-lowering show the same benefits

In other words, it's simply not possible, if you really stop and think about it.

Claim #6: "LDL doesn't cause heart disease, it's inflammation/insulin resistance/oxidation/etc."

This often repeated group of claims represents a fundamental misunderstanding of atherosclerosis pathophysiology. The bottom line is, it's not an either/or situation. LDL (apoB) is necessary but not sufficient for atherosclerosis. So, LDL particles penetrate the arterial wall (especially when levels are elevated and particle numbers are high, and an injury to the lining is NOT REQUIRED for this to happen).

Oxidation and modification of LDL occurs in the arterial wall. So yes, oxidation matters, but it requires LDL to be stuck in there first. The oxidized LDL floating in and measurable from the blood stream is cleared quickly and not typically what's actually involved in the initiation of plaque formation.

Inflammatory response is triggered by the presence of modified LDL in the artery lining. Systemic inflammation can accelerate the whole process but it is NOT REQUIRED for it to happen.

Without LDL/apoB, you cannot develop atherosclerosis. This is already proven by:

-Genetic conditions with lifelong very low LDL (no atherosclerosis even with other risk factors)

-Animal models where removing LDL reverses atherosclerosis

-Human trials showing LDL lowering reduces events proportionally

Inflammation, oxidative stress, and insulin resistance ABSOLUTELY all contribute to atherosclerosis, but they do so mostly by contributing to endothelial dysfunction, modifying LDL and promoting its retention in the arterial wall. Addressing inflammation without lowering LDL is like trying to squirt water on a fire while continuously adding fuel to it.

Claim #7: "The LDL hypothesis has been disproven/questioned by recent research"

This is factually incorrect. The evidence has actually only gotten stronger over time:

-This new meta-analysis adds to the mountain of evidence

-Mendelian randomization studies confirm causality

-Every new LDL-lowering therapy tested has shown cardiovascular benefit proportional to LDL reduction

-No therapy that lowers LDL has failed to lower cardiovascular events (when tested in adequately powered trials)

The consistency is actually quite remarkable and supports a causal relationship.

The Bottom Line

This new meta-analysis represents:

-Over 100,000 participants

-13 major randomized controlled trials

-Consistent benefit across all trials

-30% reduction in major cardiovascular events for each 39 mg/dL LDL reduction

-Clear dose-response relationship (more LDL lowering = more benefit)

The evidence for LDL-lowering therapy in appropriate primary prevention populations is now overwhelming. The debate among credible scientists isn't whether LDL lowering works, it's now just about:

-How to best identify who benefits most (risk stratification)

-Optimal LDL targets for different populations

-How to minimize side effects (dosing strategies, alternative agents)

-Cost-effectiveness in lower-risk populations

-Other ways to lower LDL

-Best ways to address accelerating factors like inflammation and insulin resistance

For patients with elevated cardiovascular risk, the decision to lower LDL (ALWAYS FIRST through diet, lifestyle, and ONLY WHEN APPROPRIATE, medication) is truly one of the most evidence-based interventions in all of medicine.

If you're still skeptical, ask yourself:

-Am I applying the same level of scrutiny to the claims of statin critics as I am to the mainstream evidence?

-Am I relying on low quality or high quality evidence?

-What would it take to change my mind, and (if I look hard) has that threshold already been met by the existing evidence?

As a doctor who used to shun all use of statins, I have learned over the years this is not about blind faith in drugs and being duped by the pharmaceutical industry, or paid off by them, it's about looking with my own eyes at the best available evidence, then watching the response in my patients to see if it matches, which it does.

I still always work with nutrition, nutraceuticals, and various aspects of lifestyle medicine at the very least along with medication recommendations (in severe cases) if not before them. But I have let go of my skepticism of these drug interventions, both in terms of their utility and safety, even though I used to literally make all the claims above myself. At this point, having seen what I've seen, if I didn't change my mind, it could only be because I was lying to myself and to my patients.